0004-0245 : Invirase 200 mg Oral Capsule


NDC0004-0245
Labeler: Genentech, Inc.
Product Type: Human Prescription Drug
Drug Name:  Invirase
Dosage Form: Oral Capsule
Application #: NDA020628
Rev. Date: 


Appearance:


Markings: ROCHE;0245
Shapes:  Capsule
Colors:  Brown / Green
Size (mm): 22
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

ROCHE 0245: (0004-0245) Invirase 200 mg Oral Capsule by Genentech, Inc.
The above image is provided by the U.S. National Library of Medicine (NLM) and is not part of the official label.

NDC Package Codes:

  • 0004-0245-15: 270 CAPSULE IN 1 BOTTLE, PLASTIC (0004‑0245‑15)

Active Ingredients:

  • Saquinavir Mesylate

Dosage Strength:

  • 200 mg

Inactive Ingredients:

  • Anhydrous Lactose
  • Cellulose, Microcrystalline
  • Povidone K30
  • Sodium Starch Glycolate Type a Potato
  • Talc
  • Magnesium Stearate
  • Gelatin
  • Water
  • Ferric Oxide Red
  • Ferric Oxide Yellow
  • Ferrosoferric Oxide
  • Fd&c Blue No. 2
  • Titanium Dioxide

Pharmaceutical Classes:

  • HIV Protease Inhibitors [MoA]
  • Protease Inhibitor [EPC]
  • Cytochrome P450 3A Inhibitors [MoA]

Related Products:

Based on records with the same trade name.
  • 0004-0244 Invirase 500 mg Oral Tablet by Genentech, Inc.
  • 49349-624 Invirase 200 mg Oral Capsule by Remedyrepack Inc.
  • 53808-0674 Invirase 500 mg Oral Tablet by State of Florida Doh Central Pharmacy

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0004-0245 QR Code

< Prev: 0004-0244Next: 0004-0256 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.